Filing Flows › Companies › Sanara MedTech › Report card
Sanara MedTech earnings report card
Every report on file against what analysts and the company itself expected, and what the stock did
Beat rate2 of 4 reports beat the EPS estimate
Sanara MedTech (SMTI) beat the analysts' EPS estimate in 2 of its last 4 reports (50%), by -367.2% on average. On report days the stock moved 11.1% in either direction on median (largest 30.1%), rising 50% of the time. Next report: Nov 11, 2026, analysts expect EPS $0.02.
Report by report
| Quarter | Reported | EPS est. | EPS reported | Surprise | Revenue reported | Stock, the day | vs market |
|---|---|---|---|---|---|---|---|
| Q2 2026 | Aug 11, 2026 | −$0.07 | $0.09 | +223.1% | $28.1M | +0.2% | +0.3% |
| Q1 2026 | May 11, 2026 | −$0.22 | $0.04 | +118.2% | $27.8M | +11.1% | +11.0% |
| Q4 2025 | Mar 24, 2026 | $0.11 | −$0.19 | -272.7% | $27.5M | -10.9% | -11.1% |
| Q3 2025 | Nov 12, 2025 | −$0.21 | −$3.52 | -1537.2% | $26.3M | -30.1% | -28.5% |
Estimates and reported EPS are the Street's adjusted figures. Revenue reported is from the company's filing. The stock's move is close to close around the report date (the close before it to the close of the session after), against SPY for the market column.
Charts
The earnings-day move
Over 4 reports the stock moved 11.1% on median on the day (close to close), the largest move 30.1%.
The next report: what to expect → Sanara MedTech: every quarter →
Read automatically from SEC filings, earnings releases and public estimates; errors are possible. Not investment advice.